Lasa Supergenerics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Lasa Supergenerics şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

n/a

Geri Alım Getirisi

Toplam Hissedar Getirisi	n/a
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	₹0.250
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Sep 02

Recent updates

There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

Aug 08

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Jun 05

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Mar 13

Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

Dec 28

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: LASA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: LASA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Lasa Supergenerics Piyasaya Karşı Temettü Getirisi

LASA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (LASA)	0%
Pazarın Alt %25'i (IN)	0.2%
Pazarın En İyi %25'i (IN)	1.1%
Sektör Ortalaması (Pharmaceuticals)	0.7%
Analist tahmini (LASA) (3 yıla kadar)	n/a

Önemli Temettü: LASA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, LASA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: LASA Indian piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: LASA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Lasa Supergenerics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Upcoming dividend of ₹0.25 per share

Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Lasa Supergenerics Limited Approves the Recommendation of the Final Dividend for the Financial Year Ended March 31, 2022

Lasa Supergenerics Limited Approves Final Dividend for the Financial Year Ended March 31, 2021

Recent updates

Lasa Supergenerics Limited to Report Q2, 2025 Results on Nov 14, 2024

New major risk - Share price stability

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2024

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2024

New minor risk - Share price stability

First quarter 2025 earnings released: ₹0.55 loss per share (vs ₹0.99 loss in 1Q 2024)

There's No Escaping Lasa Supergenerics Limited's (NSE:LASA) Muted Revenues

Lasa Supergenerics Limited to Report Q1, 2025 Results on Aug 14, 2024

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

Full year 2024 earnings released: ₹4.34 loss per share (vs ₹7.71 loss in FY 2023)

Lasa Supergenerics Limited to Report Q4, 2024 Results on May 30, 2024

Lasa Supergenerics Limited Announces Resignation of Ravi Shankar Kabra as Chief Financial Officer

Little Excitement Around Lasa Supergenerics Limited's (NSE:LASA) Revenues As Shares Take 26% Pounding

Lasa Supergenerics Limited Appoints Umesh Pawar as an Additional Director (Executive Director)

Third quarter 2024 earnings released: ₹0.29 loss per share (vs ₹1.21 loss in 3Q 2023)

Lasa Supergenerics Limited to Report Q3, 2024 Results on Feb 13, 2024

Improved Revenues Required Before Lasa Supergenerics Limited (NSE:LASA) Stock's 25% Jump Looks Justified

Second quarter 2024 earnings released: ₹0.005 loss per share (vs ₹1.62 loss in 2Q 2023)

Lasa Supergenerics Limited to Report Q2, 2024 Results on Nov 10, 2023

Lasa Supergenerics Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: ₹0.99 loss per share (vs ₹2.97 loss in 1Q 2023)

Lasa Supergenerics Limited to Report Q1, 2024 Results on Aug 14, 2023

We Think Lasa Supergenerics (NSE:LASA) Has A Fair Chunk Of Debt

New major risk - Financial position

Full year 2023 earnings released: ₹7.71 loss per share (vs ₹1.32 loss in FY 2022)

Lasa Supergenerics Limited to Report Q4, 2023 Results on May 29, 2023

Lasa Supergenerics (NSE:LASA) Is Carrying A Fair Bit Of Debt

Third quarter 2023 earnings released: ₹1.21 loss per share (vs ₹1.16 loss in 3Q 2022)

Lasa Supergenerics Limited Announces Resignation of Ankita Shetty as Company Secretary and Compliance Officer

Lasa Supergenerics Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹1.62 loss per share (vs ₹3.38 loss in 2Q 2022)

Insufficient new directors

Lasa Supergenerics Limited to Report Q2, 2023 Results on Nov 14, 2022

Upcoming dividend of ₹0.25 per share

Lasa Supergenerics' (NSE:LASA) Dividend Will Be ₹0.25

Lasa Supergenerics Limited, Annual General Meeting, Sep 26, 2022

Would Lasa Supergenerics (NSE:LASA) Be Better Off With Less Debt?

First quarter 2023 earnings released: ₹2.97 loss per share (vs ₹0.20 profit in 1Q 2022)

Lasa Supergenerics Limited to Report Q1, 2023 Results on Aug 08, 2022

A Look At The Fair Value Of Lasa Supergenerics Limited (NSE:LASA)

Lasa Supergenerics Limited Announces Resignation of Mithun Mohan Jadhav as Director

Insufficient new directors

Lasa Supergenerics Limited Approves the Recommendation of the Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings released: ₹1.32 loss per share (vs ₹5.60 profit in FY 2021)

Lasa Supergenerics Limited to Report Q4, 2022 Results on Apr 11, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Is Lasa Supergenerics (NSE:LASA) Using Too Much Debt?

Insufficient new directors

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Lasa Supergenerics Limited Launches New Product - Oxyclozanide

Full year 2021 earnings released: EPS ₹5.60 (vs ₹0.89 in FY 2020)

Lasa Supergenerics Limited Approves Final Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

New 90-day low: ₹66.60

New 90-day low: ₹74.55

Third quarter 2021 earnings released: EPS ₹1.61 (vs ₹0.89 in 3Q 2020)

Lasa Supergenerics Limited to Report Q3, 2020 Results on Feb 01, 2021

New 90-day high: ₹88.20

New 90-day high: ₹88.00

New 90-day high: ₹81.05

New 90-day high: ₹76.55

Market bids up stock over the past week

New 90-day high - ₹71.90

New 90-day high - ₹66.95

Lasa Supergenerics Limited to Report Q1, 2021 Results on Aug 05, 2020

New 90-day high - ₹55.65

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme